GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update highlighting progress on its lead vaccine candidate GEO-MVA for mpox and smallpox, as well as its immuno-oncology platform Gedeptin. The company reported a net loss of $5.3 million for the quarter, compared to a net loss of $5.4 million in the same period of 2025.
GeoVax continues to focus on operational execution for the planned Phase 3 immunobridging clinical study of GEO-MVA, which is being developed under an expedited regulatory pathway aligned with guidance from the European Medicines Agency (EMA). The company believes this pathway could lead to accelerated regulatory authorization and commercialization, addressing the need for diversified MVA-based orthopoxvirus vaccine supply. Recent milestones include the completion and release of cGMP clinical trial material, initiation of CRO selection and trial infrastructure activation, and advancement of continuous cell-line manufacturing initiatives using the AGE1 platform to support future scalable production.
“GeoVax has strategically aligned the organization around GEO-MVA and the significant global opportunity for a diversified MVA vaccine supply,” said David A. Dodd, Chairman and CEO of GeoVax. “Our efforts are now centered on operational execution of the Phase 3 immunobridging program, supported by completed manufacturing activities, CRO selection, regulatory alignment, and advancing clinical trial initiation.” The planned Phase 3 study is expected to enroll approximately 500 participants and will evaluate neutralizing antibody responses relative to an approved MVA comparator vaccine, using established immunobridging endpoints to provide rapid clinical validation.
The company also highlighted the importance of GEO-MVA in the context of global public health preparedness and biodefense. Dodd noted that “the ongoing evolution of mpox, continued global supply constraints, and dependence on a single foreign supplier for MVA-based orthopoxvirus vaccines reinforce the importance of establishing additional scalable supply sources.” GeoVax believes GEO-MVA may play a role in addressing supply limitations and supporting stockpile and international procurement opportunities.
In its immuno-oncology program, GeoVax continues to advance Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) platform designed to enhance checkpoint inhibitor activity in solid tumors. The company recently strengthened its position through an exclusive license agreement with Emory University covering intellectual property related to Gedeptin in combination with immune checkpoint inhibitors. This aligns with the broader industry shift toward combination immunotherapy approaches. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into next-generation combination strategies, including planned neoadjuvant and first-line settings.
Financially, GeoVax reported no government contract revenue for the quarter, compared to $1.6 million in Q1 2025, which was associated with the BARDA/RRPV Project NextGen award for its COVID-19 vaccine program. That contract was terminated in April 2025. Research and development expenses decreased to $3.9 million from $5.4 million, primarily due to lower costs from discontinued BARDA activities and reduced spending on the COVID-19 program. General and administrative expenses fell to $1.4 million from $1.7 million, reflecting lower investor relations consulting costs and reduced stock-based compensation. Cash and cash equivalents stood at $1.3 million as of March 31, 2026, down from $3.1 million at December 31, 2025.
GeoVax's strategic prioritization remains on GEO-MVA, citing established MVA platform validation, expedited regulatory alignment, large existing and anticipated orthopoxvirus vaccine demand, and growing interest in diversified vaccine supply chains. The company also believes its Gedeptin program provides meaningful long-term optionality within the evolving immunotherapy landscape. Additional information can be found in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. For more details, visit www.geovax.com.
